Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency... see more

TSX:MBX - Post Discussion

View:
Post by Mbxwatcher on Jun 06, 2024 1:32pm

Analysis

One thing I know for absolute certain:
I would be very happy to trade at .75 while we wait for the launch of Kinlytic.

At them moment i dont see the catalyst for that leap but who knows what else they may have up their sleeve.....
Comment by wizzdumb on Jun 06, 2024 1:42pm
Agree. I'm surprised we haven't heard of a VTM replacement yet......lots of teases, but nothing concrete yet. 
Comment by Mbxwatcher on Jun 06, 2024 1:44pm
To me thats the only game changer in the very short term.......would love to see something on VTM
Comment by rjc7 on Jun 06, 2024 3:50pm
I'm waiting for something totally out of left field that nobody was expecting. They do hold their cards close to their chest. 
Comment by wizzdumb on Jun 06, 2024 8:23pm
That's for sure, almost to their detriment. 
Comment by mercedesman on Jun 08, 2024 4:33pm
I think this is as simple as stringing together several more quarters of better than expected margins and profits to make everyone forget about fiscal 2023. Getting annualized revenues above $30 M will help too.  Otherwise this gets taken out for a song ( but still at a premium) as K royalties get closer and closer to reality.  Investors today basically get huge Kinlytic upside ...more  
Comment by Method on Jun 08, 2024 5:26pm
  Is there an obvious buyer for Microbix? What are the precedent transaction multiples? A buyer could pay out Kinlytic as a CVR if they don't want to pay up for it. None of the analysts attribute a lot of value for Kinlytic and I struggle to understand why except conservatism. Perhaps that just means I'm too optimistic on success and revenue ramp.
Comment by mercedesman on Jun 08, 2024 10:07pm
QuidelOrtho comes to mind. $3 B MC , also a customer. but I am sure there are many more. Many public US Biotechs are looking to add revenue streams ... especially those that can be acquired at a substantial discount.  Not saying it'll happen, but the longer the general market misprices it, the more likely it is that someone in the industry gets an idea on how to make an accretive ...more  
Comment by Method on Jun 10, 2024 6:15pm
  I think it's hard for a customer to buy the QAPs business. Probably needs to be another supplier otherwise there is too much risk of losing business. Any other ideas?
Comment by mercedesman on Jun 10, 2024 10:03pm
Vertical integration happens all the time.  Mainly to secure a steady source of supply.  But if you get another revenue stream for the future as a bonus, why not?  Not saying it will happen, but it's always a real possibility. 
Comment by RICHOFFMBX on Jun 10, 2024 5:43pm
Agreed.  Some good news is that there's been more volume on the buy side of things for the last few weeks. Nobody seems to be jumping at the bid still - a lot of patience and restraint, but a marked improvement over the last 2 months for the time being, at least.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities